Replies to post #1091 on Conatus Pharmaceuticals Inc. (CNAT)

[Inoviorulez]

Conatus already had $30 mil in the bank and just received another $50 mil upfront for the deal. That means CNAT now has around $80 million dollars. You don't need that for one phase 2b trial. Plus once NVS takes the exercise option after the phase 2b starts CNAT earns another $7 million. bringing the total cash to $87 million. Plus if the company eventually wants to it can borrow $15 million in convertible loans from Novartis. If that route is taken that would bring cash to $102 million. Don't need that for the phase 2 trials at all. Plus Novartis bares all phase 3 costs. Any other questions my friend?